18889881171
Kalkine 0
countryflagUS

Amedisys Inc

Healthcare US AMED

97.32USD
0.82(0.85%)

Last update at 2025-07-08T16:50:00Z

Day Range

96.4797.44
LowHigh

52 Week Range

75.4997.36
LowHigh

Fundamentals

  • Previous Close 96.50
  • Market Cap3123.91M
  • Volume225671
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA226.54M
  • Revenue TTM2251.41M
  • Revenue Per Share TTM69.00
  • Gross Profit TTM 453.98M
  • Diluted EPS TTM-0.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 160.24M 280.23M 210.82M 170.41M 158.99M
Minority interest -0.91000M 1.09M 1.58M 1.07M 0.78M
Net income 118.61M 209.07M 183.61M 126.83M 119.35M
Selling general administrative 754.06M 711.24M 668.30M 607.93M 501.31M
Selling and marketing expenses - - - - -
Gross profit 962.77M 980.76M 886.15M 805.30M 669.72M
Reconciled depreciation 70.96M 71.27M 67.94M 54.33M 13.26M
Ebit 180.77M 251.91M 219.27M 177.47M 166.36M
Ebitda 256.44M 329.92M 293.95M 240.73M 179.62M
Depreciation and amortization 75.67M 78.01M 74.68M 63.26M 13.26M
Non operating income net other 1.70M 37.84M 2.59M 7.45M 11.21M
Operating income 180.77M 251.91M 219.27M 177.47M 155.15M
Other operating expenses 2039.42M 1962.20M 1848.10M 1776.69M 1507.43M
Interest expense 22.23M 9.53M 11.04M 14.52M 7.37M
Tax provision 42.55M 70.06M 25.64M 42.50M 38.86M
Interest income 0.18M 0.05M 0.29M 0.08M 0.28M
Net interest income -22.05000M -9.47600M -10.74600M -14.43700M -7.09200M
Extraordinary items - - - - -
Non recurring 3.01M - 4.15M 1.47M -
Other items - - - - -
Income tax expense 42.55M 70.06M 25.64M 42.50M 38.86M
Total revenue 2223.20M 2214.11M 2071.52M 1955.63M 1662.58M
Total operating expenses 778.99M 728.84M 662.73M 626.35M 514.57M
Cost of revenue 1260.42M 1233.36M 1185.37M 1150.34M 992.86M
Total other income expense net -20.52800M 28.32M -8.44900M -7.06200M 10.93M
Discontinued operations - - - - -
Net income from continuing ops 117.70M 210.17M 185.18M 127.91M 120.13M
Net income applicable to common shares 118.61M 209.07M 183.61M 126.83M 119.30M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2060.17M 1976.24M 1856.97M 1567.20M 1262.74M
Intangible assets 102.67M 101.17M 111.19M 74.18M 64.75M
Earning assets - - - - -
Other current assets 22.90M 26.41M 25.60M 13.27M 8.22M
Total liab 940.39M 869.67M 880.64M 756.46M 621.23M
Total stockholder equity 1066.51M 1051.57M 931.35M 809.22M 640.45M
Deferred long term liab - 20.41M - - -
Other current liab 382.88M -20148.22300M -3.36400M 313.12M -3.08900M
Common stock 0.04M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.04M
Retained earnings 747.92M 757.67M 639.06M 429.99M 246.38M
Other liab - 25.22M 4.98M 33.62M 5.91M
Good will 1244.68M 1287.40M 1196.09M 932.68M 658.50M
Other assets - 39.34M 73.31M 174.63M 0.01M
Cash 145.86M 40.54M 42.69M 81.81M 30.29M
Cash and equivalents - - - - -
Total current liabilities 473.72M 355.53M 374.28M 456.34M 326.94M
Current deferred revenue - 20411.00M 295.20M 60.00M 261.08M
Net debt 341.35M 497.40M 502.92M 225.23M 295.79M
Short term debt 62.60M 49.02M 44.23M 40.54M 37.70M
Short long term debt 36.31M 15.50M 12.99M 10.50M 8.23M
Short long term debt total 487.21M 537.94M 545.61M 307.04M 326.08M
Other stockholder equity 318.55M 293.86M 292.25M 379.19M 394.01M
Property plant equipment - 16.03M 119.69M 23.72M 28.11M
Total current assets 496.94M 388.96M 356.68M 361.98M 350.55M
Long term investments 66.10M 60.50M 53.10M 14.20M 35.70M
Net tangible assets - -336.99300M -375.92900M -197.64400M -82.79800M
Short term investments - - - - -
Net receivables 328.17M 296.79M 274.96M 255.15M 237.60M
Long term debt 361.86M 419.42M 432.07M 204.51M 232.26M
Inventory - 25.22M 13.43M 11.77M 74.44M
Accounts payable 28.24M 43.73M 38.22M 42.67M 31.26M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 55.00M 44.97M 1.52M 1.06M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - - - 0.01M
Additional paid in capital - - - - -
Common stock total equity - 0.04M 0.04M 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - 757.67M 639.06M 429.99M 246.38M
Treasury stock - -461.20000M -435.86800M -319.09200M -251.24100M
Accumulated amortization - - - - -
Non currrent assets other -35.23800M -20391.66400M 19.92M 19.00M 18.91M
Deferred long term asset charges - - - - -
Non current assets total 1563.23M 1587.28M 1500.28M 1205.21M 912.19M
Capital lease obligations 89.04M 103.03M 100.54M 92.03M 87.30M
Long term debt total - 419.42M 432.07M 204.51M 232.26M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -15.63700M -5.20000M 17.00M -0.21000M -7.14400M
Change to liabilities -43.31000M -4.35300M 69.50M 30.44M 19.13M
Total cashflows from investing activities -94.48600M -281.60700M -287.10800M -352.94800M -22.19300M
Net borrowings -13.29600M 230.17M -29.24900M 56.03M -86.38300M
Total cash from financing activities -30.43300M 55.13M -14.97700M 227.21M -267.42400M
Change to operating activities -95.70800M -108.63500M 22.17M 4.12M 27.59M
Net income 117.70M 210.17M 185.18M 127.91M 120.13M
Change in cash 8.36M -37.58800M -13.13300M 76.26M -66.13400M
Begin period cash flow 45.77M 83.36M 96.49M 20.23M 86.36M
End period cash flow 54.13M 45.77M 83.36M 96.49M 20.23M
Total cash from operating activities 133.28M 188.89M 288.95M 202.00M 223.48M
Issuance of capital stock - - - - -
Depreciation 70.96M 71.27M 67.94M 54.33M 13.26M
Other cashflows from investing activities -72.68400M 0.14M -298.77700M -344.85000M -8.49100M
Dividends paid 1.56M -3968.00000M -3562.00000M -3187.00000M 143.95M
Change to inventory - - -2.03700M 7.12M 22.20M
Change to account receivables -14.23000M -18.03000M 2.11M -24.14600M 12.22M
Sale purchase of stock -25.33200M -116.77600M -54.49300M -9.55600M -187.97200M
Other cashflows from financing activities -1774.60100M 723.60M 742.72M 436.76M 192.57M
Change to netincome 48.67M 38.66M 5.77M 50.24M 46.31M
Capital expenditures 7.21M 6.72M 5.33M 7.89M 6.56M
Change receivables -14.23000M -18.03000M 2.11M -24.14600M 12.22M
Cash flows other operating -1.47500M -12.56000M -3.28400M -1.74300M 11.63M
Exchange rate changes - - - - -
Cash and cash equivalents changes 8.36M -37.58800M -13.13300M 76.26M -66.13400M
Change in working capital -105.04400M -131.01800M 26.22M -31.35600M 42.98M
Stock based compensation 16.56M 23.81M 26.73M 25.04M 17.89M
Other non cash items 9.73M -29.91100M 9.43M 12.61M 8.95M
Free cash flow 126.07M 182.17M 283.62M 194.11M 216.93M

Peer Comparison

Sector: Healthcare Industry: Medical Care Facilities

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMED
Amedisys Inc		 0.82 0.85% 97.32 - 20.28 1.34 2.81 1.50 26.12
HCA
HCA Holdings Inc		 -0.02 0.0053% 378.96 13.19 13.66 1.13 293.44 1.77 8.22
FSNUY
Fresenius SE & Co KGaA ADR		 -0.11 0.88% 12.33 16.87 9.44 0.42 0.78 0.79 5.37
FSNUF
Fresenius SE & Co. KGaA		 - -% 50.29 16.76 9.62 0.42 0.79 0.78 5.31
JDHIY
JD Health International Inc		 - -% 5.10 62.50 35.97 0.30 2.32 0.16 3.90

Reports Covered

Stock Research & News

View All

Profile

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Amedisys Inc

3854 American Way, Baton Rouge, LA, United States, 70816

Key Executives

Name Title Year Born
Mr. Paul Berthold Kusserow Chairman & CEO 1961
Mr. Scott G. Ginn Exec. VP, CFO & Acting COO 1969
Mr. Pete Hartley CTO & Sr. VP of Bus. Operations Systems NA
Mr. Michael P. North Chief Information Officer 1965
Ms. Jennifer Guckert Griffin Sr. VP, Deputy Gen. Counsel, Corp. Sec. & Interim Chief Legal Officer NA
Ms. Denise Bohnert Chief Compliance Officer 1978
Kendra Kimmons VP of Marketing & Communications & Media Relations NA
Mr. Adam Holton Chief People Officer NA
Mr. John Nugent Chief Acquisitions Officer NA
Ms. Janet Britt Sr. VP of Billing & Collections NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.